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San The novel indoloquinone compound EO-9 is shortly to undergo phase I clinical evaluation as a
potential bioreductive drug. Preclinical studies have shown that EO-9 has greater activity against cells derived
from human solid tumours than leukaemias in vitro. The results of this study extend the preclinical data
available on EO-9 by demonstrating that EO-9 induces a broad spectrum of activity (IC5, values range from 8
to 590 ng ml-') against a panel of human and munrne tumour cell lines. Some evidence exists of selectivity
towards leukaemia and human colon cell lines as opposed to murine colon cells. The response of cells to
Mitomycin C were not comparable to EO-9 suggesting that the mechanism of action of these compounds is
different. The cytotoxic properties of EO-9 under aerobic conditions are significantly influenced by extracel-
lular pH. Reduction of pH from 7.4 to 5.8 increases cell kill from 400. to 95g. in DLD-l cells. In addition.
EO-9 is unstable at acidic pH (T, = 37 min at pH 5.5) compared to neutral pH T, = 6.3 h). The major
breakdown product in vitro was identified as EO-5A which proved relatively inactive compared to EO-9
(IC, = 50 and 0.6 ug ml-' respectively). These studies suggest that if EO-9 can be delivered to regions of low
pH within solid tumours. a therapeutic advantage may be obtained.
In the search for new anti cancer drugs a series of novel
indoloquinone compounds, based on the prototype bioreduc-
tive alkylating agent Mitomycin C (MMC), have been syn-
thesised (Oostveen & Speckamp, 1987). The lead compound
in this series. EO-9 [3-hydroxy-5-aziridinyl-l-methyl-2-(lH-
indole-4, 7-dione)prop-fren-a-ol] (Figure 1) has recently been
selected for phase I clinical evaluation on the basis of good
activity against human solid tumours over murine leukaemias
in vitro and activity against several munrne tumour models
and human tumour xenografts in vivo (Winograd et al..
1989). Bioreductive alkylation is considered to play an
important role in the mechanism of action of EO-9 with the
enzyme DT-diaphorase (NAD(P)H:(quinone acceptor)
oxidoreductase (EC 1.6.99.2)) occupying a central role (Wal-
ton & Workman. 1990). It is believed that the two electron
reduction of EO-9 via DT-diaphorase generates a reactive
intermediate which can then undergo nucleophilic addition
within biologically important molecules.
The concept of bioreductive activation stems from observa-
tions that hypoxic cells within a solid tumour mass exist in
an environment that is more conducive to reductive reactions
than their well oxygenated counterparts (Lin et al.. 1972). In
addition to regions of hypoxia, solid tumours are known to
possess several other properties which may influence the final
outcome of chemotherapy. In particular. solid tumours are
known to contain regions of low pH (Wike-Hooley et al..
1984) generated as a result of a combination of poor blood
supply. the production of lactic acid and the hydrolysis of
ATP (Tannock & Rotin. 1989). The potential relevance of
this established feature of solid tumour biology to determin-
ing anti-tumour responses is highlighted by several studies
which demonstate that compounds containing the aziridine
ring structure (e.g. ThioTEPA and several aziridinyl benzo-
quinones) are more potent in acidic rather than neutral pH
conditions (Ahktar et al., 1975; King et al.. 1984; Groos et
al., 1986; Phillips et al., 1988). Similar studies have demon-
strated that a reduction in extracellular pH potentiates MMC
induced DNA cross links in EMT6 cells (Kennedy et al..
1985). The aim of this study is 2-fold; firstly. to extend the
preclinical data on EO-9 by comparing the response of a
panel of human and murine tumour cell lines following
exposure to EO-9 and MMC and secondly. to assess the
influence of extracellular pH on the cytotoxic potency of
EO-9 in vitro.
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Materials and methods
Cell lines and culture conditions
A panel of human and murine tumour cell lines was employ-
ed. details of which are presented in Table I. All tumour cell
lines, with the exception of K562 and WEHI-3B cells, were
maintained as monolayer cultures in RPMI 1640 culture
medium supplemented with 10% foetal calf serum, sodium
pyruvate (1 mM). penicillin streptomycin (50 IU ml-' 50 tg
ml-') and buffered by HEPES (25 mm). K562 and WEHI-3B
cells were maintained as suspension cultures in RPMI 1640
as described above.
Drugs
Formulated EO-9 was kindly provided by the New Drug
Development Office of the EORTC. EO-9 was reconstituted
in RPMI 1640 culture medium and stored at - 20C until
required (no loss of cytotoxic activity was observed over a 2
month period despite repeated thawing and freezing). MMC
was provided by the National Cancer Institute.
Chemosensitivitv studies
Cells were harvested from stock cultures in exponential
growth and between 0.5 and 1 x I04 viable cells in 180gl of
RPMI 1640 were plated into 96 well culture plates. Following
an overnight incubation at 37'C. 20gl of drug solution at an
appropriate concentration were added to each well (8 wells
per drug exposure) to yield a range of final EO-9 and MMC
concentrations of 1 ng ml-' to 1 gLg ml-'. Following a 4 day
incubation at 37°C in an atmosphere contaiing 5% CO, and
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Fiure 1 The chemical structure of EO-9.
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Table I The response of a panel of human and munrne tumour cells
following continuous exposure (% h) to EO-9 and MMC
EO-9 MMC
ICQ±s.d. ICu>±s.d.
Cell line Cell line characteristics (ng ml-') (ng ml-'
MAC 15A Murine ascitic tumour derived 430±50 46±17
from a solid adenocarcinoma
colon (Phillips et al.. 1990)
MAC 16 Slow growing. cachectic munrne 21±9 NA
adenocarcinoma colon
(Phillips et al.. 1990)
MAC 26 Well differentiated munne 590± 50 50± 15
adenocarcinoma colon
(Phillips et al., 1990)
WEHI-3B Murine myelomonocvtic 95± 50 75±23
leukaemia
(Warner et al.. 1969)
K562 Human chronic myelogenous 15±4 76± 11
leukaemia
(Lozzio & Lozzio. 1975)
HCLO Human adenocarcinoma of the 8± 3 55±4
colon
HCT-18 Human adenocarcinoma of the 13±3 183±31
colon
HRT-18 Human adenocarcinoma of the 8±3 87±48
rectum
(Tompkins et al.. 1974)
HT-29 Human adenocarcinoma of the 18± 10 64±21I
colon
(Fogh & Trempe. 1975)
DLD-1 Human adenocarcinoma of the 28±20 133±47
colon
(Dexter et al.. 1979)
MCF-7 Derived from a pleural effusion 17±8 150± 32
of a human breast carcinoma
(Soule et al.. 1973)
All results presented are the means (±s.d.) of three independent
expenments. NA = data not available.
95%0 air. chemosensitivity was assessed using the MTT assav
(Jabbar et al.. 1989). Verv briefly. 150 gl of old medium was
removed and replaced with 150gil of fresh medium immedi-
ately prior to the addition of 20 gIl of MTT solution (5 mg
ml-'). Following a 4 h incubation at 37°C. 180 gil of medium
plus MTT was removed from each well and the formazan
crystals dissolved in 150 gil of DMSO. The absorbance of the
resulting solution was read at 550 nm using an ELISA spec-
trophotometer. All results were expressed in terms of per cent
survival taking the control absorbance values to represent
100% survival. Cytotoxic effects were expressed as IC_%
values (concentration required to reduce cell surVival by
50%). All control cultures were in exponential growth at the
time chemosensitivity was assessed.
The influence ofpH on the c}vtotoxicpotency ofEO-9
MCF-7 and DLD-1 cell lines were considered to be the most
appropriate cells to investigate the effect of pH on the cyto-
toxic properties of EO-9 principally because oftheir ability to
form multicellular spheroids. As the response of spheroids
and monolayers to EO-9 is the subject of future studies. an
assessment of the influence of pH on EO-9 induced cell kill
would have a bearing on the interpretation of these studies.
MCF-7 and DLD-1 cell lines were harvested from stock
cultures and I x 104 cells transferred to flat bottomed 96 well
plates containing 200gil of RPMI 1640 and incubated over-
night at 37C. Extracellular pH was altered by removing
195 gil of medium and replacing it with 180 gil of media at
various pH values (pH was altered by adding small aliquots
of 0.1 N NaOH or 0.1 N HCI to 10 ml of RPMI 1640). EO-9
(20gIl at the IC50 value of 0.625gigml-') was added to each
well and incubated at 37C for 1 h. Following drug exposure
cells were washed twice in Hanks balanced salt solution and
chemosensitivity was assessed by the MTT assay described
above. Control cultures at various pH were employed through-
out. As an additional control experiment, the influence of pH
on the cytotoxic properties of the novel nitrosourea. E10
(N-fN'-(2 chloroethyl)-N'-nitroso-carbamoyl]-L-alanine, Ehres-
mann et al., 1984) were assessed using a 1 h exposure to
5 gig ml- 1. E10 is currently being evualated in this laboratory
and was a gift from Prof. G. Eisenbrand. Kaiserslautern.
Germany.
Stability ofEO-9 in RPVI 1640
As the stability of MMC in vitro is strongly dependent upon
pH (Verweji et al.. 1990) similar studies were conducted with
EO-9. These studies in conjunction with the characterisation
of the cytotoxic properties of the breakdown products in
vitro would help to determine whether or not any increase in
cy-totoxic potency of EO-9 at low pH was due to increased
reactivity of the compound itself or to the generation of a
more cytotoxic breakdown product. Stability studies were
conducted in RPMI 1640 culture medium at 37°C and at
various pH values.
Chromatographic analysis of EO-9 in medium was based
upon procedures published elsewhere (Kooistra & Workman.
1989). EO-9 was extracted from RPMI 1640 using C18 Bond
Elut cartridge that had been primed with methanol (1 ml)
and washed with distilled water (1 ml) prior to the addition
of the sample (1 ml). Following a further washing step (I ml
distilled water). EO-9 was eluted in 200 gl methanol. The
internal standard used was WV14 (Orlemans et al.. 1989).
The extraction efficiency of EO-9 (1 gig ml') and WV14 was
72 and 83% respectively. Extracted samples were injected
into the HPLC and compounds were separated on a RP 18
column using an isocratic mobile phase of methanol H2O
phosphate buffer (0.5 _M) (45 54 1 00 v v) at a flow rate of
1.2 ml min-'. Compounds were detected at 280 nm (Waters
spectrophotometer) and peak areas integrated using a Waters
740 data module. Drug concentrations were plotted against
time. First order kinetics were assumed and log linear regres-
sion analysis used to determine the line of best fit. The half
life was defined as the time taken for the drug concentration
to decrease by 50%.
Identification ofbreakdown products in vitro
Breakdown products in vitro were generated by the addition
of distilled water (2 ml) and a catalytic amount of acetic acid
(50gil of 5 M solution) to a solution of EO-9 (5.8 mg in 2 ml
of acetonitrile). The reaction was allowed to proceed at 25'C
for 3 h during which time aliquots (20gil) were removed for
spectroscopic monitoring of the reaction. The reaction solu-
tion, kept in a water bath at 40-45'C was evaporated to
dryness under a stream of nitrogen gas. and the resulting
solid freed from residual acetic acid by placing in a vacuum
oven. Analysis of the product by mass spectrometry. UV
spectroscopy and HPLC were conducted.
Results
Chemosensitivitv in vitro
The responses of a panel of human and munrne tumour cell
lines following continuous exposure to EO-9 are presented in
Table I. A broad spectrum of activity exists ranging from the
relatively resistant cell lines. MAC 15A and 26 (ICO values of
430 and 590 ng ml-' respectively) to sensitive cell lines partic-
ularly HCLO and HRT-18 (IC0= 8 ngml-'). Human colon
cell lines (plus MCF-7) and the leukaemia cell lines tested
were generally more responsive than the MAC cell lines with
the exception of MAC 16 which is sensitive to EO-9 (IC_%
= 21 ng ml-'). Furthermore, the spectrum of activity induced
by EO-9 and MMC are not comparable (e.g. the cell line
HCT-18 is very responsive to EO-9 whereas it is the most
resistant line to MMC; Table I).EO-9, pH AND CHEMOSENSITIVITY 361
The influence ofpH on the cytotoxic potency ofEO-9
The pH of RPMI 1640 was adjusted using aliquots of 0.1 N
HCI determined from the calibration curve presented in
Figure 2. Once adjusted, the pH of the medium remained
stable over a 1 h period at 37C (Figure 2). The responses of
MCF-7 and DLD-1 cells exposed to EO-9 (1 h exposure to
0.625 ig ml-') in medium at different pH values are present-
ed in Figure 3. Decreasing the extracellular pH below 7.5
significantly increases the cytotoxic potency of EO-9. Survival
values at pH 7.4 and 5.8 were 60 and 5% respectively (Figure
3) in the case of DLD-1 cells and 55% and 7% for MCF-7
cells respectively. Increasing the pH above 7.5 had little or no
effect on chemosensitivity. In the case of DLD-1 cells expos-
ed to EIO, decreasing the extracellular pH had no significant
effect on cell survival with a 1 h exposure to 5 gg ml- 1 induc-
ing cell kills of between 25 and 15% over a range of pH
values (pH 5.5 to 8.0).
The stablilitv ofEO-9 in vitro
The breakdown of EO-9 in RPMI 1640 medium at 37°C and
at various pH values is presented in Figures 4 to 6. EO-9 is
unstable under cell culture conditions with a half life of 6.3 h
7.5
(Figure 4). One major breakdown product was observed
which increased rapidly over the first 24 h before gradually
plateauing (Figure 4). The breakdown of EO-9 significantly
increased as the pH of the medium was reduced from 9.0 to
5.5 (Figure 5). The half life of EO-9 in RPMI 1640 medium
at pH 9.0, 7.5, 6.0 and 5.5 was 12 h, 6.3 h, 2.5 h and 37 min
respectively (Figure 5).
The identification ofthe breakdown product ofEO-9 and its
cytotoxicproperties in vitro
Chromatograms of EO-9 and its major breakdown product
generated under acidic conditions are presented in Figures 6a
and b respectively. Analysis of the breakdown product by
HPLC showed that the product was a single compound
(retention time 4.2 min) with less than 0.1% residual EO-9
remaining (retention time 5.3 min). Mass spectral data of
EO-9 (Figure 7a) showed a molecular ion at 288.112 (100%)
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Figue 2 The volume of acid (0.1 N HC1) required to reduce the
pH of RPMI 1640 medium (10 ml) at room temperature (0 0)
and the pH of medium following a 1 h incubation at 3TC
(O~O).
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Figure 4 The stability of EO-9 (0 0) in RPMI 1640 medium
at 37°C (pH 7.4) and the generation of a major breakdown
product (U-U). Concentration of the breakdown product is
expressed in terms of EO-9 equivalents.
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Figue 3 The influence of pH on the cytotoxic potency of EO-9
(1 h exposure to 0.625JLgml-') against MCF-7 (0 0) and
DLD-1 (* *) cells in vitro. The broken lines A, B and C
denote the lowest recorded tumour pH, the mean tumour pH and
the mean normal tissue pH respectively as observed by Wike-
Hooley et al. (1984).
0 20 40 60 80
Time (mins)
100 120
Fiue 5 The influence of pH on the stability of EO-9 in RPMI
1640 medium at 3rC; pH 9.0 (*-*), 7.5 (*-*), 6.0 (U-U)
and 5.5 (0-0). Values in parenthesis denote half life.
I
T
I
t
,
I vl I :o362 R.M. PHILLIPS et al.
10.00-
.- II
T
l--
-BP 2
-BP 1
E09
-BP3
Figure 6 HPLC chromatograms of a. EO-9 in phosphate buffer
at pH 7.5. b. EO-9 following a 3 h incubation in phosphate buffer
(pH 4.5) at room temperature. Three breakdown products were
detected. BPI (the major breakdown product) and BP 2 and BP3
(minor break down products).
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8a). Figure 8b shows the UV spectral changes in phosphate buffer at pH 4.6 that accompany the hydrolysis of EO-9 and
the subsequent formation of the major breakdown product. EO-9 has a UV maximum at 271 nm (molar absorbance =
19.220) which shifts with increasing absorbance to 278 nm
(24,020) (breakdown product). Similarly the peak at 312 nm
(12,010 (EO-9)) shifts to 324 nm (11,860) (breakdown pro- duct). The breakdown product showed a new peak at 211 nm
(17,770). Isobestic points are observed at 320 nm, 305 nm,
263 nm and 237 nm. These data are consistent with those of
EO-5A(3-hydroxymethyl-5-(2-hydroxylethylamino)-l-methyl- 2-(1H-indole47-dione)-prop--en--ol) as described by Binger and Workman (1990).
In order to determine the relative cytotoxic properties of
EO-9 and its major breakdown product, MAC 15A cells
were continuously exposed to a range of drug and break-
down product concentrations and chemosensitivity assessed
using the MTT assay. The results presented in Figure 9
demonstrate that the breakdown product is significantly less
cytotoxic than EO-9 in vitro (ICO = 50 and 0.6 ftg ml-'
respectively).
Discuio
The results presented in Table I clearly demonstrate that
EO-9 is not only cytotoxic under standard cell culture condi-
tions (5% CO. 95% air) but that it is capable ofinducing a
broad spectrum of activity in the panel of cell lines tested
(IC_v range = 8 to 590 ng ml-'). The spectrum of activity
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Figre 7 Mass spectral data on a. EO-9 and b. its major break-
down product in vitro.
mass units by high resolution dynamic scanning (C15H,6N204 requires 288.111) and fragments at 270 (16%), 257 (33%),
241 (51%), 229 (27%), 227 (28%), 213 (25%). The break-
down product generated following acid hydrolysis (5.1 mg, 16.7 JLmoles, 83% yield) had a melting point of 176°C. Its
mass spectrum (Figure 7b) showed a molecular ion at
306.126 (100%) mass units by high resolution dynamic scan-
ning (C15H18N,05 requires 306.122) and fragments at 290
(23%), 275 (50%), 257 (63%), 227 (41%).
Figure 8 shows the UV spectra of EO-9 in phosphate
buffer at pH 7.5 and pH 4.6. The UV spectra of EO-9 at pH
7.5 remain stable over 30 min at room temperature (Figure
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Figue 8 a, LV spectra ofEO-9 (20 jig ml-') in phosphate buffer at room temperature over a period of 30 mins (6 runs at 5 min
intervals). b, The change in UV spectra of EO-9 (20 iLg ml-') in
phosphate buffer (pH 4.6) at room temperature over a period of
I h (7 runs at time 0. 5. 10, 15. 20. 40 and 60min).
100
90+
80-
_ 70-
co
.. 60-
>50
co 40-
30+
20.
10-
0
1E-04 1E-03 1E-02 lE-01 1E+00 1E+01 lE+02
Concentration (jLg ml-')
Figue 9 The response of MAC 15A cells to EO-9 (0-0) and the isolated breakdown product (0-0) in vitro (continuous exposure).
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presented in this study is similar to that reported by Roed et
al. (1989) although it differs from previous reports (Winograd
et al.. 1989) in that no evidence of selectivity towards cells
derived from human solid tumours over leukaemias exists in
this study. Some evidence of selectivity towards leukaemia
and human colon cell lines as opposed to MAC cell lines
does however exist (Table I). Good responses in vitro to
EO-9 have been shown to translate into good anti tumour
activity in vivo (Roed et al.. 1989) and a similar correlation
exists in the case of MAC 16 cells where both the cell line is
sensitive to EO-9 (ICO = 21 ng ml-') and good anti tumour
activity in vivo has been reported (Sleigh et al.. 1989). If this
relationship holds true for other cell lines. then the possibility
exists of conducting an -in vitro phase II' trial the aim of
which would be to identify those tumour types that are most
likely to respond to EO-9 in the clinic.
The reasons for the broad spectrum of activity observed
are not known although the enzymology of the individual
cell lines may be highly significant. Enzymes such as DT-
diaphorase are believed to play a central role in the bioacti-
vation of EO-9 (Walton & Workman. 1989) and a good
correlation between the response of two MAC tumours and
DT-diaphorase activity has been reported (Workman et al..
1990). Similarly. the levels of DT-diaphorase in the HT-29
cell line are believed to be high (unpublished data in Work-
man et al.. 1990) which also correlates with good sensitivity;
to EO-9 in this study (ICio = 18 ng ml-'). On the other hand.
the good activity of EO-9 against the K562 cell line (IC^ =
15 ng ml- ) does not correlate with the fact that DT-dia-
phorase levels in this cell line are low (Beyer et al.. 1987).
Further studies to characterise the activity of various enzymes
within the panel of cell lines employed are currently in
progress.
In terms of translating in vitro chemosensitivity data into
anti tumour activity in vivo. numerous problems exist (Phil-
lips et al.. 1990). This is particularly true in the case of
bioreductive drugs where standard cell culture conditions do
not mimic the complex tumour microenvironment against
which these compounds are designed to act. Whilst drug
exposure conditions in vitro can be modified to incorporate
some of the features of solid tumour biology (such as low
oxygen tension. pH etc). the fact that EO-9 is cytotoxic
against cells under standard cell culture conditions suggests
that well oxygenated cells within a solid tumour may also be
a target. Provided sufficient quantities of EO-9 are delivered
to a tumour for long enough. it is conceivable that any
anti-tumour responses obtained may be due to a combination
of direct cytotoxicity against aerobic cells as well as bio-
activation in regions of hypoxia.
A comparison between the activity of EO-9 and MMC in
vitro (Table I) demonstrates that major differences in the
patterns of chemosensitivity exist suggesting that the mechan-
isms of action of these compounds is not the same. Studies in
other laboratories have demonstrated that unlike EO-9.
MMC is not a good substrate for DT-diaphorase (Workman
et al.. 1989). It is also known that under aerobic conditions
several enzyvme systems are capable of activating MMC such
as NADPH cytochrome P450 reductase. xanthine oxidase.
some flavoprotein transhydrogenases (e.g. er-throcyte cyto-
chrome K; reductase) as well as DT-diaphorase (Verweij et
al.. 1990). Whilst the role of these enzymes in the activation
of EO-9 are not fully understood, subtle differences in the
substrate specificity of EO-9 and MMC may account for the
different spectrum of activity observed.
Whilst differences between MMC and EO-9 exist. the two
compounds are similar in that their stability and cytotoxic
properties are pH dependent. Both EO-9 and MMC become
more unstable (Figure 9 and Verweij et al.. 1990) and more
active (Figure 3 and Kennedy et al.. 1985) as the pH is
reduced. Two possible explanations may account for this
property of EO-9. The first is that the metabolism of EO-9
by DT-diaphorase is enhanced under acidic conditions in a
manner that is analogous to that of MMC (Seigel et al..
1990) and secondly, that the chemical reactivity of the azri-
dine ring is enhanced under acidic conditions. In the case of
MMC. Seigel et al. (1990) demonstrated that the metabolism
of MMC by HT-29 cell cytosol (dicoumarol inhibitable) was
pH dependent and increased as the pH was reduced to 5.8.
For this mechanism to occur. it is essential that the intracel-
lular pH decreases in line with a drop in extracellular pH.
Kennedy et al. (1985) using flow cytometric analysis of the
dye. 1.4 diacetoxy-2.3-dicyanobenzole. demonstrated that a
decrease in extracellular pH is accompanied by a similar but
smaller decrease in intracellular pH. On the other hand.
measurements of intracellular pH by Magnetic Resonance
Spectroscopy have shown that the intracellular pH of cells
within tumours is in fact neutral or slightly alkaline
(Griffiths. 1991). In this case it is doubtful that an increase in
the metabolism of EO-9 by DT-diaphorase within the cell
will explain the observations presented in this study.
Alternatively. the chemical reactivity of EO-9 may be
enhanced at low pH values. It is known for instance that the
reactivity of aziridine groups is facilitated by protonation
resulting in the opening of the aziridine ring to release ring
strain energy (Mossoba et al.. 1985). This generates an azinr-
dinium ion which is a potent alkylating species (Lindford.
1973: Gutierrez. 1989). Increased reactivity of the aziridine
ring has been proposed to explain the increased DNA cross
linking activity of MMC and azinridinyl benzoquinones (Akh-
tar et al.. 1975: Kennedy et al.. 1985). Facilitation of
aziridine ring opening may similarly explain the increased
cytotoxic potency of EO-9 in acidic conditions particularly as
the major breakdown product of EO-9 in vitro (EO-5A) is
relatively inactive (Figure 9 and Bailey et al.. 1991). Finally.
the fact that the activity of El0 is not influenced by low pH
together with similar reports using doxorubicin. epirubicin
and epodyl (Groos et al.. 1986) suggest that the subjection of
tumour cells to low pH stress does not in itself make the cells
more sensitive to any cytotoxic insult.
The therapeutic implications of these results are not
known. particularly in view of the controversy concerning the
pH of malignant tissues (Wike-Hooley et al.. 1984: Griffiths.
1991). Nevertheless, a review of microelectrode measurements
of normal and malignant tissue pH (extracellular) demon-
strates that the pH of tumour tissue is lower than that of
normal subcutis or muscle tissue (Wike-Hooley et al.. 1984).
When these figures are superimposed upon Figure 3. the cell
kill induced at the lowest recorded pH of 5.8 is significantly
greater than that at the mean pH of normal tissues which
suggests in these cases that a therapeutic advantage may be
obtained.
In conclusion. the results of this study demonstrate that
major differences in the inherent chemosensitivity of individ-
ual cell lines to EO-9 do exist. Further studies are required to
determine whether or not the responses observed in vitro
translate into antitumour activity in vivo and to correlate
enzyme activity in each cell line with cvtotoxic effects in vitro.
If the correlation is strong. then the targetting of EO-9
against particular tumour types in the clinic may become a
viable proposition. The demonstration that the cytotoxic pro-
perties of EO-9 are influenced by extracellular pH in vitro
introduces another variable factor that may influence the
final outcome of chemotherapy in vivo.
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